Interestingly, administration of HSA-Trx reduced plasma ALT and AST levels even after the onset of NASH pathogenesis, suggesting HSA-Trx could restore liver injury (Fig. 2E and F). Here, TXN is linked to metabolic dysfunction-associated steatohepatitis.